Ischemic Optic Neuropathy Treatment Market Size, Share | 2031

Report Description

Ischemic Optic Neuropathy Treatment Market Outlook 2031

The global ischemic optic neuropathy treatment market size was USD 199.8 Mn in 2022 and is likely to reach USD 267.6 Mn by 2031, expanding at a CAGR of 3.3% during 2023–2031. Market growth is attributed to the rising incidences of ischemic optic neuropathy and increasing advancements in medical research.

Increased awareness among healthcare professionals and the general population about the importance of early diagnosis and treatment of ischemic optic neuropathy is anticipated to significantly boost the market. Growing advancements in genomic and precision medicine lead to the rising adoption of personalized treatment options for improving patient health outcomes.

Get Free Sample Report

Ischemic optic neuropathy (ION) refers to a condition where there is insufficient blood flow to the optic nerve, leading to damage and in some cases, vision loss. The two main types of ischemic optic neuropathy are anterior ischemic optic neuropathy (AION) and posterior ischemic optic neuropathy (PION).

The market report finds that the COVID-19 pandemic hampered the market. The pandemic has led to the disruptions in healthcare services globally, with resources and attention often directed towards managing COVID-19 cases. Non-urgent medical procedures and routine appointments are delayed or rescheduled, which impacts the diagnosis and treatment of conditions such as ION.

Impact of Artificial Intelligence (AI) on the Ischemic Optic Neuropathy Treatment Market

Artificial Intelligence (AI) is expected to boost the revenue of the market players present in the market. This technology has the potential to enhance early detection and diagnosis of diseases including those affecting the optic nerve. AI algorithms analyze medical images such as retinal scans and optic nerve images to identify patterns associated with ION or other eye conditions. Early detection allows for timely intervention and management.

 Ischemic Optic Neuropathy Treatment Market Dynamics

Major Drivers

Growing aging population drives the ischemic optic neuropathy treatment market. Ischemic optic neuropathy is prevalent in older individuals. As people age, the risk of developing age-related eye diseases, including ION, increases. Physiological changes associated with aging such as vascular changes and reduced blood flow lead to a high incidence of ION among the elderly. For instance,

• As per a recent data published in February 2023, individuals aged 65 and older are anticipated to double over the next three decades, reaching approximately USD 1.6 billion in 2050.

Existing Restraints

High treatment costs associated with ischemic optic neuropathy hampers the market. High treatment costs place a substantial financial burden on patients, which limits their ability to afford necessary medications, procedures, and therapies. This results in delayed or insufficient treatment that hampers patient outcomes.

Emerging Opportunities

Rising technological advancements creates lucrative opportunities for the market. Technological advancements lead to the development of sophisticated and accurate diagnostic tools. This advancement enhanced imaging techniques such as optical coherence tomography (OCT) and magnetic resonance imaging (MRI), which enables early and precise diagnosis of ischemic optic neuropathy by allowing for timely intervention.

Get Free Sample Report

Scope of the Ischemic Optic Neuropathy Treatment Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Ischemic Optic Neuropathy Treatment Market Segment Insights

Drug Class Segment Analysis

Based on drug class, the ischemic optic neuropathy treatment market is divided into antimetabolites, anticoagulants, corticosteroids, serotonin, and norepinephrine reuptake inhibitors (SNRIs). The anticoagulants segment is expected to hold a dominant share of the market during the projection period, as it provides prevention of thrombosis.

Ischemic optic neuropathy is frequently associated with thrombosis, the formation of blood clots. Anticoagulants are effective in preventing thrombosis by inhibiting the coagulation pathway. This preventive action is particularly relevant in patients with risk factors such as cardiovascular diseases, and diabetes that incline them to clot formation.

The corticosteroids segment is expected to expand at a significant pace in the coming years, as it offers anti-inflammatory properties. Corticosteroids such as prednisone and dexamethasone have potent anti-inflammatory properties. In the cases of ischemic optic neuropathy, inflammation plays a role in the damage to the optic nerve. Corticosteroids help mitigate inflammation by potentially reducing the severity of optic nerve damage.

Get Free Sample Report

Route of Administration Segment Analysis

On the basis of route of administration, the market is segregated into injectable and oral. The oral segment is projected to register a high CAGR during the forecast period, as it provides convenience to patients during medicinal intake. Oral medications are often preferred by patients due to their convenience and ease of administration.

Oral medications are generally more acceptable to patients as compared to injections or other delivery methods, which can enhance compliance with the prescribed treatment regimen. This high level of patient compliance boosts their popularity and thus, the market. The injectable segment is projected to expand at a considerable pace during the projection period, as it provides a rapid onset of action and offers precision in drug delivery.

Injectable medications often provide a faster onset of action than oral medications. In the cases of ischemic optic neuropathy where prompt intervention is crucial, the ability of injectables to deliver the medication directly into the bloodstream or target tissues is advantageous. Furthermore, injectable formulations allow for precise drug delivery by ensuring that the medication reaches its target with a high degree of accuracy.

Disease Type Segment Analysis

Based on disease type, the ischemic optic neuropathy treatment market is segmented into posterior ischemic optic neuropathy and anterior ischemic optic neuropathy. The posterior ischemic optic neuropathy segment is anticipated to register a robust growth during the forecast period, as it provides a unique pathophysiological mechanism and treatment approach.

Posterior ischemic optic neuropathy often involves different pathophysiological mechanisms compared to other forms of ischemic optic neuropathy. Tailoring treatment approaches to address the unique characteristics of PION leads to the development of specialized therapies.

Distribution Channel Segment Analysis

On the basis of distribution channel, the market is divided into retail pharmacies, hospital pharmacies, online pharmacies, and drug stores. The retail pharmacies segment is expected to generate a major revenue share of the market, as it offers easy accessibility & convenience to individuals and provide immediate access to medications.

Retail pharmacies are easily accessible to the general population by offering a convenient and familiar setting for patients to obtain their prescribed medications. They provide immediate access to medications and allow patients to start their treatment promptly after receiving a prescription. In conditions such as ischemic optic neuropathy, where timely intervention is crucial, the immediate availability of medications at retail pharmacies is advantageous for patients.

The hospital pharmacies segment is anticipated to gain significant revenue share, as it is widely used in emergency care settings and availability of specialized medications & formulation. Hospital pharmacies are well-equipped to handle specialized medications and formulations that are required for the treatment of ischemic optic neuropathy. This includes intravenous medications, high-dose therapies, or other formulations that are not readily available in retail settings. Hospital pharmacies play a crucial role in acute and emergency care settings, where patients with ischemic optic neuropathy require immediate attention and intervention.

Regional Outlook

In terms of region, the global ischemic optic neuropathy treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period due to the presence of advanced healthcare infrastructure and growing technological advancements.

North America is recognized for its well-developed and advanced healthcare infrastructure, which provides access to advanced medical facilities, specialized healthcare professionals, and cutting-edge technologies for the diagnosis and treatment of ischemic optic neuropathy. Additionally, countries in the region consistently adopt technological advancements in the healthcare industry.

This includes diagnostic tools, imaging techniques, and treatment modalities that contribute to accurate diagnosis and effective management of ischemic optic neuropathy. For instance,

•  In January 2021, Eli Lilly and Company acquired Prevail Therapeutics Inc., introducing an innovative approach to drug development.

The market in Europe is projected to grow rapidly during the forecast period, owing to growing research & development activities and high healthcare spending. Europe is home to prominent R&D hubs that foster collaboration between academic institutions, research organizations, and pharmaceutical companies.

This collaboration facilitates the continuous development of innovative treatments and therapies for ischemic optic neuropathy. Furthermore, emerging economies in the region allocate a significant portion of their budgets to healthcare, enabling substantial investments in medical research, clinical trials, and the development of new therapeutic options.

Get Free Sample Report